Rydex Inverse 2X S&P Select Se News - REC | Aktien New York Börse

RECORDATI : SHAREHOLDERS APPROVE THE 2014 ACCOUNTS.

RECORDATI SHAREHOLDERS APPROVE THE 2014 ACCOUNTS. DIVIDEND € 0.50 PER SHARE (+51.5% vs 2013). Shareholders approve the 2014...

RECORDATI : BOARD APPROVES THE 2014 ACCOUNTS.

RECORDATI; BOARD APPROVES THE 2014 ACCOUNTS. REVENUES € 987.4 MILLION (+4.9%), OPERATING INCOME € 231.0 MILLION (+18.2%), NET...

RECORDATI : PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT

PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT, SALES +4.9%, OPERATING INCOME +18.2% AND NET INCOME...

RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014

RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014. SALES +6.3%, OPERATING INCOME +18.8% AND NET INCOME +18.1%. Consolidated...

RECORDATI : CARBAGLU(R) RECEIVES ORPHAN DRUG DESIGNATION IN THE U.S. FOR ORGANIC ACIDEMIAS

MILANO, Italy, July 3, 2014 (GLOBE NEWSWIRE) -- Recordati announces that the U.S. Food and Drug Administration (FDA) has granted approval of...

RECORDATI FINALIZES THE SECOND TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA.

MILANO, Italy, May 26, 2014 (GLOBE NEWSWIRE) -- Recordati announces, following its previous releases dated 24 July 2013 and 31 October 2013, the...

RECORDATI: SALES GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT IN THE FIRST QUARTER 2014

Consolidated revenue € 260.4 million, +6.5%. EBITDA(1) € 71.4 million, +16.4% Operating income € 62.2 million...

RECORDATI: SHAREHOLDERS APPROVE THE 2013 ACCOUNTS. DIVIDEND EU 0.33 PER SHARE.

Shareholders approve the 2013 results: Consolidated revenue € 941.6 million, +13.7%, operating income € 195.4 million, +17.0...

RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS.

MILANO, Italy, March 6, 2014 (GLOBE NEWSWIRE) -- RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS. REVENUE € 941.6 MILLION (+13.7...

The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare ...

LA DEFENSE, France, Feb. 26, 2014 (GLOBE NEWSWIRE) -- EURORDIS (European Organisation for Rare Diseases) announced yesterday that Orphan Europe...

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Rydex Inverse 2X S&P Select Se (REC)

Professionelle Tools für Privatanleger.

REC Nachrichten

RECORDATI : SHAREHOLDERS APPROVE THE 2014 ACCOUNTS.

RECORDATI : BOARD APPROVES THE 2014 ACCOUNTS.

RECORDATI : PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT

RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014

RECORDATI : CARBAGLU(R) RECEIVES ORPHAN DRUG DESIGNATION IN THE U.S. FOR ORGANIC ACIDEMIAS

RECORDATI FINALIZES THE SECOND TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA.

RECORDATI: SALES GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT IN THE FIRST QUARTER 2014

RECORDATI: SHAREHOLDERS APPROVE THE 2013 ACCOUNTS. DIVIDEND EU 0.33 PER SHARE.

RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS.

The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare ...

RECORDATI : PRELIMINARY 2013 RESULTS SHOW SIGNIFICANT GROWTH. SALES +13.7%, EBIT +17.0%, NET INCOME +12.8%.

RECORDATI : OBTAINS VITAROS(R) LICENSE FROM APRICUS BIOSCIENCES

RECORDATI BOARD OF DIRECTORS APPROVES 2014 OBJECTIVES

RECORDATI : FINALIZES THE FIRST TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA

RECORDATI REPORTS SIGNIFICANT GROWTH IN THE FIRST NINE MONTHS 2013

REC Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Rydex Inverse 2X S&P Select Se (REC) News

Rydex Inverse 2X S&P Select Se (REC)

Professionelle Tools für Privatanleger.

REC Nachrichten

RECORDATI : SHAREHOLDERS APPROVE THE 2014 ACCOUNTS.

RECORDATI : BOARD APPROVES THE 2014 ACCOUNTS.

RECORDATI : PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT

RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014

RECORDATI : CARBAGLU(R) RECEIVES ORPHAN DRUG DESIGNATION IN THE U.S. FOR ORGANIC ACIDEMIAS

RECORDATI FINALIZES THE SECOND TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA.

RECORDATI: SALES GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT IN THE FIRST QUARTER 2014

RECORDATI: SHAREHOLDERS APPROVE THE 2013 ACCOUNTS. DIVIDEND EU 0.33 PER SHARE.

RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS.

The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare ...

RECORDATI : PRELIMINARY 2013 RESULTS SHOW SIGNIFICANT GROWTH. SALES +13.7%, EBIT +17.0%, NET INCOME +12.8%.

RECORDATI : OBTAINS VITAROS(R) LICENSE FROM APRICUS BIOSCIENCES

RECORDATI BOARD OF DIRECTORS APPROVES 2014 OBJECTIVES

RECORDATI : FINALIZES THE FIRST TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA

RECORDATI REPORTS SIGNIFICANT GROWTH IN THE FIRST NINE MONTHS 2013

REC Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen